FDA Targets Generics Manufacturer Mylan for Continuous Quality Problems, an Industrial Info Market Brief
FDA Targets Generics Manufacturer Mylan for Continuous Quality Problems, an Industrial Info Market Brief
Attachment: mylan
Generics manufacturer Mylan once enjoyed an ongoing clean safety record with the U.S. Food and Drug Administration (FDA). Today, the company is finding itself repeatedly in the agency's spotlight due to problems with quality. With a vast global network of manufacturing plants, the company produces active pharmaceutical ingredients (APIs) for a wide range of generic drug products, along with final formulations.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum
- Africa's Fertilizer Demand Sparks $5.8 Billion of Projects
- Poland's PGE Plans $7 Billion Renewable Energy Push
- Peru's Runoff Presidential Election Could Impact $45 Billion in Mining Proj...
- Industrial Construction Activity Up 37% So Far in 2021